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Material and Methods: 100 CT datasets of cervical cancer 
patients (stage IB2 – IIIB) receiving HDR application (50 
tandem-ovoid and 50 tandem-ring) were studied. The 
external beam radiotherapy dose was 50Gy. Brachytherapy 
was delivered using a CT-MRI compatible tandem-ovoid (50 
patients) and a tandem-ring applicator (50 patients) to a dose 
of 8Gy/# in 2fractions. Bladder and rectum were contoured 
using oncentra planning system. DVHs were calculated and 
D2cc was recorded for bladder and rectum and compared 
with the corresponding ICRU point doses. The point B dose, 
the treated volume, high dose volume and the treatment 
time was recorded and compared for the two applicators. 
 
Results: 
 
Applicator 
Mean 
D2cc 
Bladder 
(Gy) 
Mean 
ICRU 
Bladder 
(Gy) 
Mean 
D2cc 
Rectum 
(Gy) 
Mean 
ICRU 
rectum 
(Gy) 
ICRU/D2cc 
ratio 
Bladder 
ICRU/D2cc 
ratio 
Rectum 
Tandem-
Ring 6.57 5.56 3.95 5 0.847 1.265 
Tandem-
ovoid 7.30 5.63 4.79 5.65 0.772 1.179 
 
Conclusion: The results indicate that the OAR doses assessed 
by DVH criteria were higher than ICRU point doses for bladder 
with both tandem-ovoid and tandem-ring applicators whereas 
DVH based dose was lower than ICRU dose for rectum. The 
point B dose, the treated volume and high dose volume was 
found to be slightly higher with tandem-ovoid applicator 
whereas the total treatment time was higher with the 
tandem-ring applicator. The mean D2cc dose for bladder and 
rectum was lower with tandem-ring applicators. The clinical 
implication of the above dosimetric differences needs to be 
evaluated further. 
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Purpose or Objective: The aim of this study is to evaluate an 
accurate method to define vaginal dose distribution in the 
delivery of vaginal vault brachytherapy (VBT) utilising a 
single channel cylinder. 
 
Material and Methods: A retrospective analysis of all 3D 
single channel cylinder VBT plans held on BrachyVision™ 10.0 
treatment planning system obtained between April 2011 and 
December 2013. All patients received treatment to the top 
4cm of the vagina at 0.5cm depth prescription point with 
fractional doses of 5.5Gy or 7Gy. Dose assessment is 
conducted using both point dose values and DVH parameters 
for vaginal wall. A vaginal apex dose point (VAdp) was 
defined as a midline point on the single channel cylinder, 
positioned at the apex representing vaginal surface dose 
(Gy). A second rectal / vaginal dose point (RVdp), positioned 
0.5cm posterior to vaginal wall (ICRU rectal point) is also 
used. This is potentially a good surrogate for vaginal mucosa 
dose due to its proximity to vaginal cylinder. A presumed 
vaginal wall thickness of 0.5cm was used to grow a volume 
representing the upper 4 cm of vaginal mucosa; the D2cc (Gy) 
and D5cc (Gy) are recorded. Pearson’s correlation coefficient 
is used to calculate correlation between dose point values 
and dose volume parameters obtained. A p-value <0.05 was 
considered statistically significant in this study. 
 
Results: A total of 113 CT data sets are analysed. 69% (n = 
78) of patients had a prescribed fractional dose of 5.5Gy and 
31% (n = 35) received 7Gy fractional dose. 
 
 
 
No correlation was identified between RVdp and D2cc for 
5.5Gy plans (r=0.004, p=0.974) and 7.0Gy plans (r=0.009, 
p=0.957). Similarly no correlation was identified between the 
RVdp and D5cc for 5.5Gy plans (r=0.170, p=0.138) and 7.0Gy 
plans (r=0.071, p=0.687). The D2cc showed a weak 
correlation with VAdp for 5.5Gy (r=0.200, p=0.083) and 7Gy 
plans (r=0.351, p=0.039); however only statistically 
significant with 7Gy plans. No relationship exists between 
VAdp and D5cc for 5.5Gy (r=0.146, p=0.202) and 7Gy plans 
(r=0.068, p=0.699).  
 
Conclusion: The RV dp is not a good surrogate for vaginal 
dosimetry. The VAdp could possibly be considered to predict 
D2cc values however dose volume parameters remain the 
accurate method when recording dose to vaginal mucosa 
from delivery of VBT. 
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Purpose or Objective: The aim of this study is to establish 
whether one initial CT planning scan for vaginal vault 
brachytherapy (VBT) patients is adequate to ensure 
surrounding OAR (bladder, rectum, sigmoid colon and small 
bowel) do not breach their dose constraints, or whether 
patients should be CT planned before each VBT fraction due 
to variations in OAR volumes and organ movement. 
 
Material and Methods: Patients were scanned twice with a 
segmented single central channel vaginal cylinder in situ. The 
first CT scan (A) was carried out, as per departmental 
protocol, two weeks prior to treatment delivery and the 
subsequent scan (B) on the first day of treatment. All 
patients were treated using scan A. OAR dose deviations were 
retrospectively calculated by applying the same dwell 
positions and loadings to scan B. The total EQD2 OAR dose 
received by VBT and EBRT was then assessed for tolerance 
breach (bladder 80Gy; rectum, sigmoid colon and small bowel 
70Gy). Both scans were analysed using Pearson correlation 
coefficient to determine relationships between % differences 
of OAR volumes and the OAR D2cc dose % differences. 
Additional bladder, rectum and GI structure (sigmoid colon 
and small bowel) contours were created combining the two 
scans (A+B); to simulate the worst case scenario structure 
movement between treatments. 
 
Results: 42 patients were scanned twice in total. 5 patients 
were prescribed 21Gy in 3 fractions after 45Gy in 25 fractions 
EBRT, 27 patients were prescribed 11Gy in 2 fractions after 
45Gy in 25 fractions EBRT and 10 patients were prescribed 
21Gy in 3 fractions of VBT only. Scan B CT plans showed all 
patients receiving VBT only or EBRT with 2 fractions of VBT 
had total EQD2 doses within published OAR dose tolerances. 4 
out of 5 (80%) patients treated with EBRT and 21Gy of VBT 
exceeded at least one OAR dose tolerance and when contours 
were combined 100% of these patients exceeded at least one 
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OAR dose tolerance. No relationship was identified between 
the % difference of OAR volumes and D2cc OAR % variations. 
 
Conclusion: Patients treated with 45Gy in 25 fractions EBRT 
+ 21Gy in 3 fractions VBT are at greater risk of breaching OAR 
dose tolerances when using a single planning scan for all 
treatments. There is no significant relationship between the 
% difference of bladder, rectum, sigmoid and small bowel 
volumes and % dose difference. The OAR dose variation 
between each scan is most likely due to the unpredictable 
day to day movement of the structure and cannot be 
replicated by standardised organ filling procedures. 
Departmental protocols have been amended to CT plan this 
subgroup of patients before each treatment fraction to take 
into account position of structure at that time. Use of a 
multichannel applicator could also help minimise the dose to 
these structures. 
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Purpose or Objective: A report of late rectal and bladder 
toxicitiy outcomes of a computed tomography(CT)-based 
image guided brachytherapy(IGBT) technique for treatment 
of cervical cancer.  
 
Material and Methods: Between 2008-2014, 95 women with 
International Federation of Gynecology and Obstetrics stage 
IB to IVA cervical carcinoma treated with definitive 
concurrent cisplatin based chemotherapy and external beam 
radiation therapy (EBRT) 50.4Gy in 28 fractions followed by 
3-4 fractions of high-dose-rate (HDR) IGBT was 
retrospectively reviewed. At each implantation, all patients 
had a urinary catheter insitu and received bowel enema 
before undergoing planning CT-simulation. A high-risk clinical 
target volume (HRCTV) encompassing any visible tumor and 
the entire cervix, rectum and bladder was contoured on the 
simulation CT according to Radiation Therapy Oncology Group 
Gynaecology Contouring Atlas. Prescription dose range of 5.5-
7Gy was prescribed to the HRCTV. Doses to Point A, ICRU 
rectal and bladder points were recorded. Toxicities were 
recorded using NCI-CTCAE version 3. 
 
Results: The median follow-up time was 29 months. The 
mean Point A dose was 6Gy (4.6-7.6Gy). The ICRU rectum and 
bladder points were 4.69Gy (2.5-5.7Gy) and 4.23Gy (1.95-
7.2Gy) respectively. 22 patients(23%) and Grade 2 proctitis 
and 10 patients(11%) had Grade 3 proctitis. 4 patients (4%) 
had Grade 2 cystits and 2 patients(2%) had Grade 3 cystitis. 
No patients had ≥ Grade 4 toxicity.  
 
Conclusion: Despite bladder and bowel preparation protocol, 
late rectal toxicity was significant in a high proportion of 
patients. Implementation of an interstitial IGBT using the 
EMBRACE protocol might help to limit these late rectal 
toxicities. 
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Purpose or Objective: To analyze the preliminary results of 
a new daily high-dose-rate brachytherapy (BT) schedule in 
vaginal-cuff relapse (VCR) and toxicity in postoperative 
endometrial carcinoma (EC). 
 
Material and Methods: From September 2011 to December 
2014, 102 patients (p) were treated with HDRBT in FIGO 
stages: IA-30p, IB-39p, II-8p, IIIA-4p, IIIB-1p, IIIC1-8p, IIIC2-
5p, IIIC3-1p, IVB-6p. Pathology: 79/102 endometrioid 
adenocarcinoma and 23/102 other types. Radiotherapy: 
Group 1: 74p/102p 1 BT fraction of 7Gy after external beam 
irradiation (mean 45Gy, range 44.0-50.4); Group 2: 28p/102p 
BT alone by 3 daily fractions of 6Gy. Chemotherapy: 20/102 
patients. Toxicity evaluation: RTOG scores for bladder and 
rectum and the objective criteria of LENT-SOMA for vagina. 
Statistics: Chi-square and Fisher exact tests. 
 
Results: Mean age (years): Group 1: 65.4 (40-88), Group 2: 
66.7 (39-90). Mean follow-up (months): Group 1: 24.48 (8.04-
52.56); Group 2: 26.88 (8.76-54.48). VCR: No relapses with 
the present mean follow-up. Toxicity: Group 1 - early 
problems (all G1-2) in rectum (5.5%), bladder (6.8%) and 
vagina (14.9%). Late toxicities: rectum 2.7% (all G1), bladder 
0% and vagina 27% (G1-G2). Group 2 -early toxicity: bladder 
10.7% (all G1), vagina 28.1% (all G1-G2), rectum 0%; late 
toxicity was only found in vagina in 17.8% (G1-2). No 
significant differences were found in toxicities between the 
two groups. 
 
Conclusion: The present brachytherapy schedule consisting 
in 1 fraction/7Gy after external beam irradiation and 3 
fractions/6Gy administered daily seem a safe regime in terms 
of local control and toxicity for postoperative EC. These 
results seem similar to those found in our Hospital in 2 
previous series with low dose per fraction and an increased 
number of fractions. Grant: AECC Foundation 
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Purpose or Objective: To develop a reliable method of 
determining the radiation dose to the vaginal mucosa in the 
treatment of cervical cancer. 
 
Material and Methods: Forty six cervical cancer patients 
were treated with EBRT and HDR brachytherapy therapy from 
July 2010 – Dec 2013. They received 45Gy in 25 fractions of 
EBRT to the entire pelvis followed by 3 HDR brachytherapy 
fractions using a tandem and ring applicator with a HRCTV 
D90 of 80-85Gy. A volume to represent the vaginal mucosa 
was obtained by using a non-uniform expansion of the 5mm 
ring applicator cap; this was expanded by 5.0 mm in all 
directions except the sup/inf which was expanded by 7.0 
mm. In addition, a rectal vaginal (RV) point dose was 
determined using a point 5.0 mm posterior to the 
intersection of the superior-posterior junction of the build up 
cap (figure 1 sagittal view). Total doses were calculated for 
vaginal volumes of 5.0cc (D5 v), 2.0cc (D2 v), and the RV 
point. In addition, the slope was calculated for the vaginal 
mucosa between D5 v and D2 v. Pearson correlation 
coefficients (with p values = 0.01) were assessed to identify 
